SOR-C13

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameSOR-C13
Drug Alias NameSOR-C13
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTransient receptor potential cation channel subfamily V member 6 antagonists
TargetsTransient receptor potential cation channel subfamily V member 6
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSoricimed
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesSoricimed Biopharma Inc
Active IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A